News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Girishanthy Krishnarajah, MPH, MBA/MS, PhD

Articles by Girishanthy Krishnarajah, MPH, MBA/MS, PhD

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
October 21st 2016

Trending on AJMC

Four Major Idiopathic Pulmonary Fibrosis Advances From 2026

Machine Learning Has High Accuracy, Little Prospective Validation in MPNs

The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?

BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence

HHS Draft Policy Eases Enforcement on 6 Compounded Peptides